This asset is highly complementary to our Phase 3 FSGS program and broadens our development footprint across the kidney disease continuum, from acute injury through to chronic disease." Dr Nina Webster, CEO & Managing Director, Dimerix Limited #Dimerix #KidneyDisease #RareDisease #Biopharma #DrugDevelopment #ClinicalTrials #Nephrology #PrecisionMedicine #HealthcareInnovation #Biotech To view or add a comment, sign in ICYMI: Early phase 1 data from Bambusa Therapeutics suggests #BBT001 delivered rapid, durable improvements in atopic dermatitis severity and itch, with sustained biomarker suppression, favorable safety, and the potential for dosing as infrequently as every 3 months
If you are also considering other treatments, explore options like Wegovy through our service
cut their weekly food and alcohol spending by an average of 36%, saving up to $6,754 and 4,425 annually
It might work for you too, but don't be discouraged if it doesn't
Does retatrutide really reduce liver fat
Also read this: The Truth About Ozempic Injection: The Most Revolutionary Weight Loss Drug of the Decade Who Is Trulicity Injection Suitable For